Hiding in Plain Sight: Soluble Immunomodulatory Receptors

Lekh N Dahal; Herbert Schwarz; Frank J Ward

doi:10.1016/j.it.2018.08.004

Hiding in Plain Sight: Soluble Immunomodulatory Receptors

Trends Immunol. 2018 Oct;39(10):771-774. doi: 10.1016/j.it.2018.08.004. Epub 2018 Sep 5.

Authors

Lekh N Dahal¹, Herbert Schwarz², Frank J Ward³

Affiliations

¹ Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton, UK. Electronic address: L.N.Dahal@soton.ac.uk.
² Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
³ Immunity, Infection and Inflammation Programme, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.

PMID: 30195467
DOI: 10.1016/j.it.2018.08.004

Abstract

Alternatively spliced natural soluble isoforms of immunomodulatory receptors [cytotoxic T lymphocyte antigen-4 (CTLA-4), 4-1BB, and programmed death-1 (PD-1)/PD-L1] have been overlooked in favor of their cell-surface-bound counterparts that have generated blockbuster antibodies for the treatment of cancer. We propose that the soluble variants of these receptors contribute to immune regulation and offer potential as targets for immunotherapy.

MeSH terms

Animals
Antibodies, Monoclonal / therapeutic use*
B7-H1 Antigen / immunology
B7-H1 Antigen / metabolism*
CTLA-4 Antigen / immunology
CTLA-4 Antigen / metabolism*
Humans
Immunotherapy / methods*
Molecular Targeted Therapy
Neoplasms / immunology
Neoplasms / therapy*
Programmed Cell Death 1 Receptor / immunology
Programmed Cell Death 1 Receptor / metabolism*
Tumor Necrosis Factor Receptor Superfamily, Member 9 / immunology
Tumor Necrosis Factor Receptor Superfamily, Member 9 / metabolism*

Substances

Antibodies, Monoclonal
B7-H1 Antigen
CTLA-4 Antigen
Pdcd1 protein, mouse
Programmed Cell Death 1 Receptor
Tumor Necrosis Factor Receptor Superfamily, Member 9